Advanced MRI Measures of Repair in Alemtuzumab Treated Patients — iCAMMS-IST  

Relapsing Remitting Multiple Sclerosis Clinical Trial

Official title: Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients

Status Completed

Clinical Trial Summary

There are two parts to this investigator sponsored trial (IST):

1. To perform advanced serial MRI studies on patients initiating alemtuzumab therapy.

2. To provide serum samples for the University of Southern California (USC) ICAM125 lymphocyte recovery study.

Clinical Trial Description

Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the Central Nervous System (CNS). There are many forms of MS; although the majority are Relapsing Remitting (RRMS) representing approximately 80% of the cases. The disease appears to be more inflammatory in RRMS as manifested by an increase in Gadolinium (Gd) enhancement on MRI and an increase in inflammatory bio-assay markers.

Alemtuzumab; a humanized monoclonal antibody that targets the CD52 molecule present on T and B lymphocytes, natural killer (NK) cells, and monocytes and macrophages; effects rapid and sustained lymphocyte depletion and is approved for the treatment of B-cell chronic lymphocytic leukemia in many countries under the names CAMPATH or MabCAMPATH.

There are two parts to this Investigator Sponsored Trial (IST):

1. To perform advanced serial MRI studies on patients initiating alemtuzumab therapy.

2. To provide serum samples for the University of Southern California (USC) ICAM125 lymphocyte recovery study. ;

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Relapsing Remitting Multiple Sclerosis
• Sclerosis

• NCT number: NCT01307332
• Study type: Interventional
• Source: University of British Columbia
• Status: Completed
• Phase: Phase 3
• Start date: March 2011
• Completion date: September 28, 2018